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Introduction
Chronic alcohol abuse causes liver pathology that progresses 
from simple steatosis through stages of steatohepatitis, followed 
by fibrosis, then cirrhosis, and finally end-stage liver disease. In 
addition to liver degeneration, chronic alcohol abuse serves as a 
potent co-factor in the pathogenesis of hepatocellular carcinoma 
(HCC). Besides liver, chronic alcohol abuse causes permanent 
injury to the brain, leading to cognitive-motor impairments and 
neurodegeneration, the cardiovascular system, resulting in heart 
failure and enhanced atherosclerosis, and various other organs 
in which it serves as a co-factor in malignant transformation. 
However, the toll of chronic alcohol abuse is heaviest in liver and 
brain. 
Alcoholic liver disease (ALD) accounts for 40% of deaths due 
to cirrhosis, and 28% of all liver disease related deaths in the US.1 
These figures correspond to 3.2–3.5% of all deaths, and 3.6% of 
all cancer deaths globally.2,3 The risk of developing hepatocellular 
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Chronic alcohol abuse causes liver disease that progresses 
from simple steatosis through stages of steatohepatitis, 
fibrosis, cirrhosis, and eventually hepatic failure. in addition, 
chronic alcoholic liver disease (ALD), with or without 
cirrhosis, increases risk for hepatocellular carcinoma (HCC). 
Acetaldehyde, a major toxic metabolite, is one of the principal 
culprits mediating fibrogenic and mutagenic effects of alcohol 
in the liver. Mechanistically, acetaldehyde promotes adduct 
formation, leading to functional impairments of key proteins, 
including enzymes, as well as DNA damage, which promotes 
mutagenesis. why certain individuals who heavily abuse 
alcohol, develop HCC (7.2–15%) versus cirrhosis (15–20%) is 
not known, but genetics and co-existing viral infection are 
considered pathogenic factors. Moreover, adverse effects of 
acetaldehyde on the cardiovascular and hematologic systems 
leading to ischemia, heart failure, and coagulation disorders, 
can exacerbate hepatic injury and increase risk for liver failure. 
Herein, we review the role of acetaldehyde adducts in the 
pathogenesis of chronic ALD and HCC. 
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carcinoma (HCC) increases with dose of chronically consumed 
ethanol1,4 and alcohol consumption in excess of 80 g/day is corre-
lated with high rates (7.2–15%) of HCC, especially in the setting 
of cirrhosis.1,3,5-7 HCC is the fifth most common malignancy, with 
an estimated half million new cases diagnosed worldwide each 
year. Prognosis is generally poor (median survival 1–2 months)8 
due to late discovery and limited effective therapeutic options. 
Only one-third of patients with HCC are deemed suitable for 
curative procedures, many of which have not yet been fully val-
idated.9 Given the role of alcohol abuse in the pathogenesis of 
both liver degeneration and HCC, along other major untreatable 
and irreversible diseases, including those that afflict the brain 
and cardiovascular system, it is imperative that we improve our 
understanding of how alcohol mediates its adverse effects.
Alcohol Metabolism
Alcohol is detoxified and eliminated primarily in the liver via a 
series of oxidative metabolic reactions.10,11 The three major steps 
are: (1) reversible oxidation of ethanol to acetaldehyde, which is 
toxic; (2) non-reversible metabolism of the toxic acetaldehyde to 
acetate; and (3) breakdown of acetate to water and carbon dioxide 
(Fig. 1). The first step in alcohol oxidative metabolism is effectu-
ated by key enzymes, including alcohol dehydrogenase (ALD), 
cytochrome P450 2E1 (CYP2E1), and catalase. ADH is the main 
oxidizing enzyme; it has a high affinity for alcohol12 and breaks 
down ethanol in the cytoplasm. CYP2E1 is utilized by a distinct 
pathway that is induced by chronic alcohol consumption, and 
results in acetaldehyde formation in peroxisomes. A third path of 
first-step ethanol metabolism is mediated by catalase oxidation of 
ethanol in microsomes.13,14
The second step, which is mainly carried out by mitochon-
drial aldehyde dehydrogenase (ALDH), is to metabolize acetalde-
hyde to acetate. In addition, acetaldehyde can be metabolized by 
CYP2E1 through an NADPH-dependent pathway (microsomal 
acetaldehyde-oxidizing system).15 The resulting acetate is unsta-
ble and spontaneously breaks down to water and CO2. When 
these oxidative mechanisms become overwhelmed, acetaldehyde 
accumulates and exerts its toxic effects. The electrophilic nature 
of acetaldehyde12 enables it to bind and form adducts, i.e. covalent 
chemical addition products, with proteins, lipids, and DNA.3,11,16-18 
Adducts are broadly pathogenic because they impair func-
tions of proteins and lipids, and promote DNA damage and 
mutation.11 review review
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Alcohol Enzyme Polymorphisms
Propensity for acetaldehyde accumulation vis-à-vis ethanol 
consumption is governed in part by genetic factors. Poly-
morphisms in the ADH and ALDH genes can affect the rates of 
acetaldehyde generation and metabolism, and therefore govern 
proneness to acetaldehyde toxicity. In humans, there are at least 
8 iso-enzymes of ADH and 4 iso-enzymes of ALDH. The most 
important ADH iso-enzymes are those encoded by the ADH1A, 
ADH1B and ADH1C genes.3,19 In addition, various ADH1B and 
ADH1C alleles account for differences in the activity of ADH. 
For example, the ADH1B*2 allele encodes an enzyme that is 40 
times more active than the one encoded by the ADH1B*1 allele. 
Rapid metabolism of alcohol to acetaldehyde, in individuals who 
express the ADH1B*2 allele, results in its toxic accumulation. 
The clinical manifestations of this effect include, flushing, sweat-
ing, tachycardia, nausea and vomiting after ethanol consumption. 
This ADH1B*2 allele is predominantly found in Asian popula-
tions. Although short-term responses to ethanol cause consider-
able discomfort, the adverse physiological response could serve 
as a deterrent for chronic alcohol misuse. The ADH1C*1 allele 
is another ADH iso-enzyme with increased (2.5-fold) activity, 
but the physiological effects associated with alcohol consumption 
are modest compared with those of ADH1B*2.3 Nonetheless, 
individuals carrying at least one ADH1C*1 allele are at increased 
risk (3.6-fold) for developing alcohol-related HCC compared 
with those who are homozygous for ADH1C*2.20 This suggests 
that genetic polymorphisms in ADH that result in increased gen-
eration of acetaldehyde also enhance ethanol’s pro-carcinogenic 
effects.
ALDH2 is encoded by two main alleles, ALDH2*1 and 
ALDH2*2. ALDH2*2 is an inactive enzyme, and when expressed, 
acetaldehyde accumulation can be 10- or 20-fold higher than 
when the ALDH2*1 active enzyme is expressed, rendering alco-
hol consumption virtually intolerable.21 The ALDH2*2 enzyme 
is not found in Caucasians, but is homozygous in 10%, and 
heterozygous in 40% of Asians.3 Low ALDH activity increases 
risk for aero-digestive cancers,22 and among Japanese people, 
the phenotype increases the risk for malignancy in general.23,24 
Together, the findings indicate that specific genetic polymor-
phisms in the ADH and ALDH genes have important roles in 
increasing susceptibility to alcohol-related cancers among heavy 
drinkers, and that the adverse effects of ethanol are likely medi-
ated through the toxic and mutagenic effects of acetaldehyde.
Roles of Alcohol and Acetaldehyde  
in Carcinogenesis 
Experimental animal models have provided convincing evidence 
that alcohol is a mutagen,3 and that acetaldehyde should be 
regarded as a carcinogen (Table 1).10,11,25,26 The role of alcohol/
acetaldehyde as a carcinogen is particularly relevant to the patho-
genesis of upper aero-digestive tract cancers.3,27 Mechanistically, 
alcohol mediates its mutagenic effects through: (1) formation 
of acetaldehyde adducts;3,28 (2) increased oxidative stress;29,30 
(3) induction of Kupffer cells by gut-derived endotoxins and 
release of TNF-α;31-33 (4) inhibition of DNA methylation; and 
(5) impairing retinoid metabolism, which is important in cell 
differentiation.1 Iron acts either independently34,35 or synergisti-
cally21,34,36 to promote the toxic and mutagenic effects of acetal-
dehyde. It is noteworthy that similar mechanisms contribute to 
the pathogenesis of chronic alcohol-induced liver injury leading 
to fibrosis or cirrhosis.
Acetaldehyde exerts its mutagenic effects by interacting 
directly with DNA,37 and causing lesions ranging from point 
mutations to more extensive chromosomal damage.22 For exam-
ple, acetaldehyde-induced point mutations in the hypoxanthine 
phosphoribosyltransferase gene (HPRT1) impair DNA synthesis, 
DNA repair mechanisms, particularly nucleotide excision and 
excision- repair processes that maintain stability and integrity of 
genomic DNA.37 In addition, acetaldehyde causes DNA damage 
by inducing sister chromatid exchanges (SCE’s).16,22 Any one of 
these mutagenic effects can activate cancer-generating pathways, 
or contribute to liver injury leading to cirrhosis.
Acetaldehyde as an Indirect Carcinogen 
(1) Acetaldehyde protein adducts. Acetaldehyde impairs cel-
lular functions and gene expression by forming adducts with 
proteins and DNA.11,16,38,39 Acetaldehyde produces protein 
adducts by interacting with the epsilon amino group of lysine, 
or the α  amino group of N-terminal amino acids.12 Stable 
acetaldehyde adducts alter the structure and function of pro-
teins, including enzymes. For example, acetaldehyde adducts 
formed with O6 methylguanine methyltransferase,22 impair 
DNA repair mechanisms, which could mediate carcinogen-
esis.40 Other major proteins targeted for acetaldehyde adduct 
formation include, tubulin,41 collagen,42 ketosteroid reductase   
Figure 1. Metabolic pathways of alcohol. The main oxidizing enzyme 
is cytosolic alcohol dehydrogenase (ADH), which converts ethanol to 
acetaldehyde. Cytochrome P450 2e1 (CYP2e1), an enzyme of the micro-
somal ethanol oxidizing system (MeOS) that is inducible with chronic 
alcohol consumption also metabolizes alcohol. The conversion of acet-
aldehyde (a toxic metabolite) to acetate is by mitochondrial aldehyde 
dehydrogenase (ALDH). Both ADH and ALDH have polymorphisms that 
affect the rate at which acetaldehyde is generated and metabolized.180  Oxidative Medicine and Cellular Longevity  volume 3 issue 3
(catalyzes reduction of key intermediates in bile acid biosynthe-
sis), CYP2E1,43 and coagulation factors 7 and 9.44 Protein adducts 
impair catalytic activity,45 and consequently, functional impair-
ment of CYP2E1 (NADPH-dependent) could lead to further 
acetaldehyde accumulation. Acetaldehyde binding to glutathione 
inhibits hydrogen peroxide scavenger function, thereby aggravat-
ing oxidative stress and lipid peroxidation.46 Lipid peroxidation 
is probably the most important mediator of alcohol-induced cir-
rhosis and carcinogenesis.31,47 
(2) Acetaldehyde DNA adducts. Acetaldehyde gener-
ates DNA adducts, the most prevalent of which is N2-ethyl-
deoxyguanosine (N2-Et-dG).22,37 N2-Et-dG is detectable in   
livers of alcohol-exposed mice, leukocytes of human alcohol 
abusers,16,22,48 and in humans with an ALDH2 genotype.49,50 
Due to its stability, N2-Et-dG is detectable in alcohol-associated 
head and neck cancers,51 and therefore could potentially serve as 
a marker of alcohol mis-use. 1,N(2)-propano-2’-deoxyguanosine 
(PdG), another acetaldehyde-DNA adduct, is distinguished by 
its genotoxic and mutagenic effects, and capacity to generate 
secondary lesions such as DNA-protein and DNA inter-strand 
cross-links16 which impair DNA replication, thereby promoting 
cell death. Acetaldehyde-DNA adducts also promote carcinogen-
esis by triggering replication errors and mutations in oncogenes 
or onco-suppressor genes.22
(3) Lipid peroxidation adducts. Alcohol’s mutagenic effects 
can be mediated by induction of CYP2E1,22,52 which results in 
increased generation of reactive oxygen species (ROS)37,52 lead-
ing to oxidative stress and cell death.11 ROS-generated radicals, 
Table 1. Mechanisms of tissue injury: ethanol, acetaldehyde and lipid peroxidation adducts
Compound Injury Effect/Disease Mechanism
Ethanol
Steatosis
Oxidative stress29,30
Cirrhosis
Carcinogenesis10,11,25,26
Triglyceride accumulation
er Stress, insulin resistance, Mitochondrial dysfunction, 
CYP2e1 induction
Acetaldehyde generation
DNA damage
Acetaldehyde
Protein/enzyme dysfunction Protein,11,12,16,22,38,39 DNA16,22,37 and hybrid adducts18,43,58
Oxidative stress
Lipid peroxidation adducts,18,22,56 Pro-inflammatory cytokine 
activation, Glutathione scavenger function inhibited, rOS 
production increased37,52
Fibrogenesis/Cirrhosis Adducts in HSCs and myofibroblasts11,64,65
Carcinogenesis Mutagenesis by binding with DNA37
Atherosclerosis Oxidation of LDL79,80,81,82,83
Cardiomyopathy impairs contractile function of cardiomyocytes86,88,90
erythrocyte macrocytosis Acetaldehyde-modified erythrocyte membrane protein107
Anemia and iron overload in 
liver
immune mediated attack on erythrocytes107
impairs coagulation function  inactivates clotting factors, e.g thrombin, fibrinogen, Factors 
ii, vii, X, Xa, Xiiia110,111,112
Lipid Adducts (MDA; 4-HNE)
Cell death Oxidative/er Stress11
Hepatic fibrosis/cirrhosis 
 
 
Hepatic stellate cell activation with induction of collagen 1 
synthesis and inhibition of pro-collagen negative feedback 
loop77, 78
Carcinogenesis
Mutagenesis, including inhibition of oncosuppressor genes, 
e.g. p5322
Atherosclerosis Auto-immune response to modified proteins82,83  
Oxidation of lipoproteins forming plaques80,81
 
Abbreviations: er stress, endoplasmic reticulum stress; CYP2e1, cytochrome P450 2e1; rOS, reactive oxygen species; HSCs, hepatic 
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including superoxide anion and hydroxyethyl radical (HER),   
are highly reactive and form adducts with lipids, proteins and 
DNA. Hydrogen peroxide, also generated through CYP2E1 
enzymatic activity, can react with metal ions such as iron, to 
produce hydroxyl radicals.37,53 Since chronic alcohol abuse causes 
iron to accumulate in liver, increases in CYP2E1 activity and 
H2O2 production can independently or synergistically exacer-
bate alcohol-induced liver injury and possibly liver cancer via 
increased hydroxyl radical formation,21,36 and attendant DNA 
strand breakage, as well as a broad range of adverse biological 
responses.37,54
ROS promotes formation of lipid peroxidation products, 
including malondialdehyde (MDA) and 4-hydroxynonenal 
(4-HNE), both of which are detectable in association with 
intense CYP2E1 immunoreactivity in oral squamous cell car-
cinoma or leukoplakia in alcoholics.55 MDA and 4-HNE can 
react with DNA bases to form exocyclic DNA adducts. In 
this regard, MDA reacts with deoxy-guanosine residues, while 
4-HNE reacts with deoxyadenosine and deoxycytidine,22,37 
yielding the adducts, 1,N6-ethenodeoxyadenosine (εdA) and 
3,N4-ethenodeoxycytidine (εdC), which have important roles 
in the pathogenesis of chronic alcohol-related liver injury.18,56 In 
addition, both εdA and εdC are highly mutagenic, and can cause 
mutations in the p53 gene.22 Specifically, these adducts induce 
G:C to T:A transversions on codon 249, and 30–40% of HCCs 
contain a mutation of p53.57
(4) Hybrid adducts. Various types of aldehydes generated 
within cells can cross-react to form hybrid adducts. For example, 
MAA hybrid adducts are composed of different combinations of 
MDA-acetaldehyde-protein adducts. The clinical significance of 
this phenomenon is that hybrid adducts can act synergistically 
and potentiate carcinogenic potential of individual adducts.18,58 
In addition, hybrid adducts may mediate stabilization of protein 
adducts,43 thereby perpetuating their genotoxic effects. 
Adducts Promote Liver Disease 
Adducts accumulate in perivenous regions (Zone 3) of rat59,60 and 
human56,61 livers, overlapping with the distribution of fatty change 
(steatosis), i.e. the earliest lesion in alcohol-induced liver injury,62 
and associated with increased serum aminotransferase levels.63 
Acetaldehyde protein adducts are detectable in alcohol-related 
disease-associated inflammation and fibrosis.11,64 Ultrastructural 
and immunohistochemical staining methods revealed that acet-
aldehyde adducts are detectable in hepatic stellate cells (HSC) in 
the context of steatofibrosis or cirrhosis, and in myofibroblasts in 
zones with bridging fibrosis.65 Liver injury is likely mediated by 
binding of acetaldehyde to lysine residues and secondary inter-
ference with lysine-dependent enzymes such as calmodulin, and 
also tubulin.11 Acetaldehyde adduct formation with 5% or less 
of the available α-tubulin pools impairs microtubular function 
and causes derangement of the hepatocyte cytoarchitecture, as 
has already been described in ALD.11 Similarly, accumulation 
of acetaldehyde and MDA adducts on areas of collagen depos-
its contributes to the formation of scar tissue, and subsequent 
hepatic fibrosis or cirrhosis.11
Aldehyde-protein adducts and hydroxyl radicals can cause 
liver injury by stimulating intense immune responses directed 
against the modified proteins, as demonstrated by antibod-
ies detected in sera of chronic alcohol-exposed experimental   
animals66 and humans.11 Sera of heavy drinkers may contain 
high titers of IgM, IgG and IgA antibodies to acetaldehyde 
adducts.67-69 Associated “auto-immune” attacks on hepatocytes 
cause necrosis,70 and with continued rounds of inflammation, 
necrosis, oxidative stress, ROS generation, and further adduct 
formation, fibrosis ensues.71 An assay for detecting IgA antibod-
ies to acetaldehyde-protein adducts has been developed and can 
be used to monitor liver injury associated with moderate to heavy 
drinking.69,72
Chronic alcohol abuse leads to progressive liver disease through 
stages of simple steatosis, to steatohepatitis, fibrosis, and finally 
cirrhosis through activation of hepatic stellate cells (HSCs). 
Stellate cells are activated by oxidative stress and lipid peroxi-
dation.73 MAA adduct treatment of cultured hepatic endothelial 
cells stimulates secretion of cytokines and chemokines, includ-
ing tumor necrosis factor-α (TNF-α), monocyte chemoattrac-
tant protein-1 (MCP-1) and macrophage inflammatory protein-2 
(MIP-2).74 In addition, MAA adducts activate HSCs by stimulat-
ing secretion of fibronectin, which leads to increased extracellular 
matrix deposition with attendant fibrosis, and eventually cirrho-
sis.75 Mechanistically, adducts generated by alcohol metabolism 
and lipid peroxidation increase collagen mRNA and connective 
tissue protein expression.43,76 Specifically, acetaldehyde induces 
collagen 1 synthesis in HSCs by activating the AP-1 transcription 
factor.77 Protein kinase C phosphorylates p70S6k, which pro-
motes protein synthesis and collagen deposition. Acetaldehyde 
also inhibits the negative feedback loop of procollagen by binding 
to the carboxyl-terminal propeptide,78 further promoting depo-
sition of fibrous matrix. Conversely, adduct scavengers such as 
chlormethiazole, abolish acetaldehyde-mediated fibrogenesis.43   
In essence, acetaldehyde adducts contribute to injury, degenera-
tion, scarring and carcinogenesis, and therefore play key roles in 
the pathogenesis of various stages of alcohol-related liver disease.3 
Acetaldehyde Effects on the Cardiovascular System: 
Contribution to Liver Injury 
While moderate consumption of alcohol has cardio-pro-
tective effects, excessive amounts worsen atherosclerosis and 
increase cardiovascular risk. Atherosclerotic plaques form in 
response to intimal accumulation of oxidized low-density 
lipoproteins (LDL) in foam cells, which promote oxida-
tive stress and inflammation.79 Since aldehyde adducts can 
mediate oxidation of lipids, including LDL, they potentially 
have an important role in the pathogenesis of atherosclerosis. 
Malondialdehyde (MDA), one of the oxidative products of 
unsaturated fatty acids and a component of atherosclerotic 
plaques, can also modify LDL. Moreover, both MDA and 
acetaldehyde can react with various proteins, including apo-
lipoprotein B-100, a component of oxidized LDL, and gener-
ate additional adducts that cause endothelial cells to produce 
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molecules that are critical mediators of atherosclerosis.80,81 
Correspondingly, atherosclerosis can be inhibited by treat-
ment with recombinant antibodies to oxidized LDL82 deplet-
ing B cells that produce autoantibodies to oxidized LDL83 
or administration of aldehyde scavengers.84 It is noteworthy 
that MAA adducts are increased in human atherosclerotic 
vessels,80 and like MDA, MAA’s pro-inflammatory properties 
can exacerbate atherosclerosis.80 Acetaldehyde toxicity and 
vascular degeneration can contribute to liver disease by caus-
ing chronic ischemic injury mediated by atherosclerosis of the 
aorta and hepatic artery. 
Acetaldehyde quite likely has a pathogenic role in alco-
hol-associated cardiomyopathy.85-89 In this regard, it is note-
worthy that in experimental animal models, acetaldehyde 
accumulation in myocardium impairs contractile func-
tion,86,88,90 disrupts cardiac excitation-contraction cou-
pling87,88,91 and promotes oxidative stress85 with attendant 
increased lipid peroxidation.87 Acetaldehyde inhibits protein 
metabolism and induces protein adducts, which together 
impair the integrity of actin and myosin filaments and depress 
cardiomyocyte contractile function. In addition, alcohol 
abuse leads to hypertension, cardiac arrhythmias, and non-
ischemic cardiomyopathy.92 Consequential reductions in car-
diac output would lead to liver injury due to chronic passive 
congestion, and also exacerbate injurious effects of chronic 
ethanol exposure or acetaldehyde formation. On the other 
hand, ALDH2 is cardioprotective against ischemic heart dis-
ease93 and acute cardiac toxicity94 because it promotes rapid 
detoxification of acetaldehyde. Correspondingly, genetic 
polymorphisms that reduce ALDH2 enzymatic activity are 
associated with increased rates of diabetes mellitus among 
Chinese women with coronary artery disease (CAD), inde-
pendent of alcohol intake,95 while over-expression of ALDH2 
in transgenic mice reduces alcohol-induced myocardial 
hypertrophy and impairments in insulin/Akt signaling.96-98 
Therefore, acetaldehyde can promote cardiovascular disease 
by several mechanisms including impairment of insulin sig-
naling and cardiomyocyte function, and inducing atheroscle-
rosis, which together could lead to liver injury mediated by 
ischemia or chronic passive congestion.
The relationship between cardiovascular disease and liver 
disease is particularly evident in regard to non-alcoholic fatty 
liver disease (NAFLD). Like alcoholic liver disease, NAFLD 
progresses through stages of increased inflammation with cell 
turnover and loss (non-alcoholic steatohepatitis; NASH), 
fibrosis, cirrhosis, and finally end-stage liver disease.99 In addi-
tion, progression of NAFLD increases ones risk for develop-
ing HCC.100 NAFLD is increasingly regarded as the hepatic 
component driving the increased risk of cardiovascular dis-
ease in individuals with diabetes mellitus, hyperlipoprotein-
aemia, or metabolic syndrome.101-104 Moreover, obesity and 
excess dietary fat intake, which are largely responsible for 
the epidemic growth in NAFLD, promote systemic oxida-
tive stress and lipid peroxidation,105 thereby contributing to 
the increased risk of cardiovascular disease. Like ALD, pro-
gression of NAFLD is associated with increased formation of 
adducts, including acetaldehyde and MAA, and MAA adduct 
accumulation correlates with severity of NASH.106 Therefore, 
NAFLD-mediated increases in acetaldehyde and hybrid 
adducts can contribute to progression of alcoholic liver disease 
via increased atherosclerosis.
Acetaldehyde Effects on Erythrocytes  
and Clotting Mechanisms 
Chronic alcohol abuse has significant adverse effects on the 
hematopoietic system including erythrocyte and coagula-
tion functions. Chronic alcohol abuse promotes red blood cell 
morphological changes such as erythrocyte macrocytosis.72,107 
This abnormality has been correlated with the presence of 
Figure 2. Proposed schematic of alcohol-mediated pathways result-
ing in hepatocellular carcinoma (HCC ). The metabolism of alcohol 
generates acetaldehyde which promotes carcinogenesis pathways. 
Acetaldehyde (AA) directly causes DNA lesions, resulting in mutations. 
indirectly AA forms covalent bonds with proteins, impairing DNA repair 
mechanisms, and increasing carcinogenesis potential. AA also binds to 
DNA, forming DNA adducts (N2-et-dG and PdG), which are mutagenic. 
Chronic alcohol consumption results in CYP2e1 induction, generating 
reactive oxygen species (rOS), thereby increasing lipid peroxidation, 
which generates MDA and 4-HNe. These lipid peroxidation products 
cause p53 mutations and form adducts with DNA. AA-protein adducts 
combine with DNA adducts to form hybrid adducts, with resultant 
synergistic activation of auto-immune attacks against hepatocytes, 
ultimately resulting in cirrhosis, which is strongly associated with HCC 
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autoantibodies to acetaldehyde-modified erythrocyte membrane 
proteins in peripheral blood107 and bone marrow aspirates108 
Potential consequences of these immune-mediated attacks on 
erythrocytes are not completely known, but they may increase 
red blood cell destruction, and thereby promote both anemia 
and iron accumulation in liver. Excessive iron accumulation is a 
well-recognized mediator of liver injury and contributes to the 
pathogenesis of alcoholic liver disease. Moreover, acetaldehyde-
bound to red blood cells can be distributed to various tissues 
and exert widespread toxic effects.109 Finally, a broad range 
of hematologic disorders can adversely affect liver function. 
For example, hemolytic anemias and hemaglobinopathies can 
result in increased iron load in the liver, as well as promote 
cholelithiasis due to increased formation of bilirubin stones. 
Alcoholic and other forms of chronic liver disease impair func-
tion of coagulation factors, but with regard to alcohol abuse, 
acetaldehyde mediates these effects by inactivating thrombin, 
Factor Xa, fibrinogen, II, VII, and X.110-112 In addition, acetal-
dehyde inhibits the transglutaminase activity of factor XIIIa,112 
and forms complexes with glycosaminoglycans to synergistically 
inhibit factors IX, IXa,111 X, and Xa,110 with consequential pro-
longation of clotting times.
Conclusions
The data strongly support the concept that chronic and exces-
sive alcohol consumption contributes to and probably promotes 
progressive liver disease and HCC. These effects of alcohol are 
mainly mediated by acetaldehyde, which is generated during 
metabolism of alcohol, and accumulates consequential to genetic 
polymorphisms in alcohol metabolizing enzymes, increased oxida-
tive stress, iron deposition in liver, and immune-mediated attacks 
on adducted proteins.  Acetaldehyde-protein and DNA adducts 
promote oxidative stress, formation of lipid peroxidation products 
(MDA and 4-HNE), HSC activation with attendant inflamma-
tion and fibrosis, and mutagenesis, and they interact with other 
aldehyde adducts to form stable hybrids that promote substan-
tially greater degrees of injury, including DNA damage (Fig. 2).
Based on these observations, we hypothesize that acetalde-
hyde accumulation → oxidative stress, inflammation, cell injury 
→ HSC activation and cytokine activation → ROS generation 
→radical ion accumulation → lipid peroxidation, DNA and 
protein adduct formation → protein and enzyme malfunction, 
impaired gene expression, and DNA damage → mutagenesis 
and fibrogenesis. In light of the potency of hybrid adducts with 
respect to accelerating and intensifying injury, it could be that 
“second hits” that perturbate metabolism and promote addi-
tional aldehyde accumulations and adducts may play pivotal 
roles in governing the path toward progressive hepatic fibrosis 
and cirrhosis versus hepatocellular carcinoma. In this regard, 
other disease states such as non-alcoholic fatty liver disease 
(NAFLD) or chronic hepatitis C virus infection, and ischemia/
hypoperfusion caused by heart failure or atherosclerosis result 
in increased accumulation of lipid peroxidation products and 
adduct formation.113,114 When combined with chronic alcohol 
abuse, these co-factors increase risk for progression to cirrhosis 
and/or HCC.115 Conditions that lead to increased iron deposi-
tion and consequently potentiate radical ion formation such as 
hemachromatosis,35 or ADH and ALDH gene polymorphisms 
that impair efficient metabolism of alcohol to carbon dioxide 
and water, could serve as co-factors in promoting end-stage 
liver disease or HCC. Finally, tobacco smoke contains nitrosa-
mines that promote adduct formation,116 and since many alco-
hol abusers smoke or are exposed to smoke, they are at increased 
risk for generating adducts unrelated to acetaldehyde-associated 
adducts. Interactions between acetaldehyde and other adducts 
resulting in the formation of hybrid adducts may represent the 
pivotal factor governing long term consequences of chronic 
alcohol abuse with respect to the development of cirrhosis or 
HCC. Future investigations will need to focus on developing 
means to detect, characterize, and quantify hybrid adducts in 
liver, and identify approaches to limit their formation and accu-
mulation in the context of chronic alcohol abuse.
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